J
Josep M. del Campo
Researcher at Hebron University
Publications - 31
Citations - 1317
Josep M. del Campo is an academic researcher from Hebron University. The author has contributed to research in topics: Ovarian cancer & Population. The author has an hindex of 18, co-authored 31 publications receiving 1060 citations. Previous affiliations of Josep M. del Campo include Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois,Anne Floquet,Jae Weon Kim,Jae Weon Kim,Joern Rau,Josep M. del Campo,Michael Friedlander,Sandro Pignata,Keiichi Fujiwara,Keiichi Fujiwara,Ignace Vergote,Nicoletta Colombo,Mansoor Raza Mirza,Bradley J. Monk,Rainer Kimmig,Isabelle Ray-Coquard,Rongyu Zang,Ivan Diaz-Padilla,Klaus Baumann,Marie Ange Mouret-Reynier,Jae Hoon Kim,Jae Hoon Kim,Christian Kurzeder,Christian Kurzeder,A. Lesoin,Paul Vasey,Christian Marth,Ulrich Canzler,Ulrich Canzler,Ulrich Canzler,Giovanni Scambia,Muneaki Shimada,Muneaki Shimada,Paula Calvert,Eric Pujade-Lauraine,Byoung Gie Kim,Thomas J. Herzog,Ionel Mitrica,Carmen Schade-Brittinger,Qiong Wang,Rocco Crescenzo,Philipp Harter +41 more
TL;DR: Pazopanib maintenance therapy provided a median improvement of 5.6 months in progression-free survival in patients with advanced ovarian cancer who have not progressed after first-line chemotherapy, and additional analysis should help to identify subgroups of patients in whom improved efficacy may balance toxicity.
Journal ArticleDOI
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Josep M. del Campo,Ursula A. Matulonis,Susanne Malander,Diane Provencher,Sven Mahner,Philippe Follana,Justin Waters,Jonathan S. Berek,Kathrine Woie,Amit M. Oza,Ulrich Canzler,M. Gil-Martin,Anne Lesoin,Bradley J. Monk,Bente Lund,Lucy Gilbert,Robert M. Wenham,Benedict B. Benigno,Sujata Arora,Sebastien Hazard,Mansoor Raza Mirza +20 more
TL;DR: Progression-free survival was improved in patients treated with niraparib compared with placebo in both the gBRCAmut cohort and the non–gBRC amut cohort, and no meaningful differences were observed between nirAParib and placebo in PR and CR subgroups with respect to patient-reported outcomes.
Journal ArticleDOI
Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab‐based therapy
Aleix Prat,Marta Parera,Vicky Reyes,Sergio Peralta,Susana Cedres,J. Andreu,Pere Huguet,Josep M. del Campo +7 more
TL;DR: A case of epidermal growth factor receptor 2 (HER2)‐positive metastatic submandibular SDC with a complete and durable clinical response to treatment with trastuzumab in combination with chemotherapy is reported.
Journal ArticleDOI
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Bradley J. Monk,Rachel N. Grisham,Susana Banerjee,Elsa Kalbacher,Mansoor Raza Mirza,Ignacio Romero,Peter Vuylsteke,Peter Vuylsteke,Robert L. Coleman,Felix Hilpert,Amit M. Oza,Anneke M. Westermann,Martin K. Oehler,Sandro Pignata,Carol Aghajanian,Nicoletta Colombo,Esther Drill,David Cibula,Kathleen N. Moore,Janna Christy-Bittel,Josep M. del Campo,Regina Berger,Christian Marth,Jalid Sehouli,David M. O'Malley,Cristina Maria Churruca,Adam P Boyd,Gunnar B. Kristensen,Andrew R Clamp,Isabelle Ray-Coquard,Ignace Vergote +30 more
TL;DR: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated and a higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimet inib.
Journal ArticleDOI
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Amit M. Oza,Ursula A. Matulonis,Susanne Malander,Stacie Hudgens,Jalid Sehouli,Josep M. del Campo,Dominique Berton-Rigaud,Susana Banerjee,Giovanni Scambia,Jonathan S. Berek,Bente Lund,Anna V. Tinker,Felix Hilpert,Isabel Palacio Vázquez,Véronique D'Hondt,Benedict B. Benigno,Diane Provencher,Joseph Buscema,Shefali Agarwal,Mansoor Raza Mirza +19 more
TL;DR: Overall QOL scores remained stable during the treatment and preprogression period in the niraparib group; no significant differences were observed between the nirkarib and placebo group, and pre Progression EQ-5D-5L scores were similar between the two groups in both cohorts.